INSIDE INFORMATION

Inside Information

GRIFOLS, S.A. guarantees that the texts published in this page correspond exactly and entirely with the texts sent to the CNMV by the Company or by third parties. All the communications are available in the Web page of the CNMV.

2021

October 26, 2021
Grifols earns approval for the voluntary public tender offer of Biotest

September 17, 2021
Grifols acquires Tiancheng Pharmaceutical Holding, the largest shareholder of Biotest

September 17, 2021
Presentation of Grifols' investment in Biotest and call details to analysts and investors

2020

June 8, 2020
COVID-19 Impacts

March 27, 2020
Grifols and Shanghai RAAS close their strategic alliance in China

March 25, 2020
Grifols has entered into a formal collaboration with U.S. healthcare agencies to produce a treatment to treat COVID-19

The information contained on the Grifols worldwide website is not applicable to all countries. For specific information on the products and services available in your country, please select your country from the list included in the corresponding section. The purpose of this website is to provide information about Grifols' products and services, and it is not intended for, nor may it be construed to, promoting any products in countries in which they are not approved.